Discontinued — last reported Q4 '22
Products & Services · Maximum potential milestone payment to be made
Tyvaso DPI — Maximum potential milestone payment to be made
United Therapeutics Tyvaso DPI — Maximum potential milestone payment to be made remained flat by 0.0% to $12.50M in Q4 2022 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $12.50M to $12.50M.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2020
Last reportedQ4 2022
How to read this metric
A high value indicates significant future cash outflows if milestones are met, representing both a financial liability and a sign of expected product progress.
Detailed definition
Quantifies the total future financial obligations contingent upon achieving specific development, regulatory, or commerc...
Peer comparison
Standard disclosure for contingent liabilities related to R&D and licensing agreements in biotech.
Metric ID:
uthr_segment_tyvaso_dpi_maximum_potential_milestone_payment_to_be_madeHistorical Data
2 years
| FY'21 | FY'22 | |
|---|---|---|
| Value | $50.00M | $50.00M |
| YoY Change | — | +0.0% |
Range$50.00M – $50.00M
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's tyvaso dpi — maximum potential milestone payment to be made?
- United Therapeutics (UTHR) reported tyvaso dpi — maximum potential milestone payment to be made of $12.50M in Q4 2022.
- How has United Therapeutics's tyvaso dpi — maximum potential milestone payment to be made changed year-over-year?
- United Therapeutics's tyvaso dpi — maximum potential milestone payment to be made decreased by 0.0% year-over-year, from $12.50M to $12.50M.
- What does tyvaso dpi — maximum potential milestone payment to be made mean?
- The total potential future payments owed if specific product goals are met.